Is It Safe to Take Metformin and Lisinopril Together?

Yes, metformin and lisinopril can be taken together and are frequently prescribed concurrently in patients with both type 2 diabetes and hypertension. However, this combination requires careful monitoring of renal function and blood pressure, as both drugs can influence kidney perfusion and metformin clearance—particularly in older adults or those with underlying kidney disease. The interaction is not a direct pharmacokinetic incompatibility but rather a cumulative effect on renal physiology that necessitates adjusted dosing and vigilant clinical oversight.

What the FDA Says

Neither the metformin nor lisinopril FDA labels explicitly contraindicate concurrent use. The metformin label (FDA-approved formulations including Glucophage and generic equivalents) notes that renal impairment is the primary concern limiting safe use, with recommendations to monitor serum creatinine and eGFR regularly. The lisinopril label (generic ACE inhibitors, brand names including Prinivil and Zestril) similarly emphasizes renal function monitoring and cautions against use in patients with severe renal artery stenosis or advanced chronic kidney disease.

The FDA Labeling via OpenFDA explicitly states that metformin is contraindicated in patients with eGFR <30 mL/min/1.73m², should be used with caution in those with eGFR 30–45 mL/min/1.73m², and requires dose adjustment or discontinuation if eGFR falls below these thresholds. Lisinopril dosing similarly requires adjustment as renal function declines. When combined, these two medications create a scenario where both the drug efficacy and the risk of adverse effects depend heavily on preserved glomerular filtration rate (GFR).

How This Interaction Works

Renal Function and Metformin Clearance

Metformin is eliminated primarily unchanged by renal excretion, with no hepatic metabolism and minimal protein binding. The drug is handled by renal tubular secretion via organic cation transporter 2 (OCT2) in the proximal tubule, making it highly dependent on active renal clearance rather than glomerular filtration alone. When renal function declines—whether from diabetes-related nephropathy or from other causes—metformin accumulates systemically, increasing the risk of lactic acidosis.

Lisinopril, an ACE inhibitor, reduces intraglomerular pressure by blocking angiotensin II-mediated vasoconstriction of the glomerular efferent arteriole. In patients with diabetic kidney disease, this hemodynamic effect is generally protective and slows nephropathy progression. However, in the acute setting of volume depletion, dehydration, or acute illness, ACE inhibitors can precipitously reduce GFR. This sudden reduction in filtration rate may trap metformin in the body faster than anticipated, especially in older adults or those with marginal baseline renal function.

Additive Hypotensive Effects

Metformin itself has no direct blood pressure-lowering properties, but ACE inhibitors like lisinopril are potent antihypertensive agents. The combination does not create a pharmacokinetic synergy, but patients on both drugs—particularly those also taking other antihypertensives—may experience more pronounced blood pressure reduction, leading to orthostatic hypotension, syncope, or reduced renal perfusion if blood pressure drops excessively.

Absence of Direct Metabolic Interaction

Metformin is not metabolized by cytochrome P450 enzymes and does not inhibit or induce CYP450 activity. Lisinopril undergoes minimal hepatic metabolism and is primarily excreted unchanged by the kidneys. There is no meaningful CYP450-mediated drug-drug interaction between these two agents. The interaction is purely physiological—driven by their collective impact on renal perfusion and filtration.

Who Is Most at Risk

Certain patient populations face elevated risk when taking metformin and lisinopril concurrently:

• Older adults (≥65 years): Age-related decline in GFR, reduced renal blood flow, and altered pharmacodynamics increase vulnerability. Many older patients taking both drugs have borderline creatinine clearance that may not be captured by serum creatinine alone.
• Patients with stage 3 or 4 chronic kidney disease (CKD): eGFR 15–59 mL/min/1.73m². These individuals are at particular risk for metformin accumulation and lactic acidosis if either drug alters renal perfusion.
• Patients with type 2 diabetes and albuminuria: Already have compromised glomerular function and may be on lisinopril specifically for renoprotection. Careful dose titration of metformin is essential.
• Patients with volume depletion or acute illness: Dehydration, sepsis, acute gastroenteritis, or contrast exposure can rapidly reduce GFR, trapping metformin and increasing lactic acidosis risk.
• Patients taking concomitant NSAIDs or other diuretics: These agents further compromise renal perfusion when combined with ACE inhibitors.
• Patients with liver disease or heart failure: Reduced hepatic perfusion or cardiac output diminishes overall renal perfusion, compounding the effect of ACE inhibition.

Clinical Scenarios

Scenario 1: A 72-Year-Old Patient with Type 2 Diabetes and Hypertension

A 72-year-old woman with type 2 diabetes (HbA1c 7.8%) and hypertension has been stable on metformin 1000 mg twice daily and lisinopril 10 mg once daily for two years. Her baseline serum creatinine is 1.3 mg/dL (eGFR approximately 48 mL/min/1.73m² using CKD-EPI, indicating stage 3a CKD). During routine follow-up, her creatinine rises to 1.5 mg/dL (eGFR drops to 41 mL/min/1.73m²) following an episode of dehydration from influenza.

Clinical decision: The pharmacist should recommend reducing metformin from 2000 mg daily to 1000 mg daily (or 500 mg twice daily), given the eGFR threshold of 30–45 mL/min/1.73m² requiring dose reduction. Lisinopril should be continued but renal function reassessed in two weeks after the acute illness resolves. If creatinine does not improve, the lisinopril dose may also need reduction. The patient should be counseled on hydration, avoidance of NSAIDs, and the importance of contacting her provider if symptoms of lactic acidosis (nausea, malaise, hyperventilation, abdominal pain) occur.

Scenario 2: A 58-Year-Old Male with Newly Diagnosed Diabetic Nephropathy

A 58-year-old man with 15 years of poorly controlled type 2 diabetes presents with stage 3b CKD (eGFR 34 mL/min/1.73m²), albuminuria (300 mg/day), and BP 148/92 mmHg. His internist initiates lisinopril 5 mg daily for renoprotection and asks whether metformin should be continued. His current metformin dose is 1500 mg daily; serum creatinine is 1.8 mg/dL.

Clinical decision: The eGFR of 34 falls into the range where metformin requires careful consideration. Per FDA guidance, metformin can be used with dose adjustment, but GFR <30 mandates discontinuation. In this case, reducing metformin to 500 mg once or twice daily is reasonable, with close monitoring of renal function every 2–4 weeks for the first two months to ensure stability. The lisinopril dose is appropriate at 5 mg daily; it may be titrated upward as tolerated to achieve BP control and albuminuria reduction. Alternative agents such as a DPP-4 inhibitor or SGLT2 inhibitor could be considered as adjunctive therapy or eventual metformin replacement if renal function declines further. Blood pressure should be monitored closely, particularly during the first two weeks of lisinopril initiation, to rule out excessive hypotension that could further compromise GFR.

What to Do: Management Guidance for Pharmacists and Clinicians

Baseline Assessment

Before prescribing or refilling metformin in a patient on lisinopril, obtain and review:

• Serum creatinine and calculated eGFR (using CKD-EPI 2021 equation preferred over MDRD)
• Baseline blood pressure and orthostatic vital signs if available
• Recent urinalysis for proteinuria or hematuria
• Patient medication list for concurrent NSAIDs, diuretics, or other renal-modifying agents
• History of acute kidney injury, volume depletion, or hepatic disease

Dose Adjustment and Monitoring Schedule

For Metformin:

• eGFR ≥60: No dose adjustment; monitor annually
• eGFR 45–59: Maximum 1000 mg daily; monitor every 6–12 months
• eGFR 30–44: Maximum 500 mg daily; monitor every 3–6 months
• eGFR <30: Contraindicated; discontinue

For Lisinopril: Standard dosing is 10 mg daily; adjust as follows for renal function:

• eGFR ≥60: Standard dosing (10 mg initial, up to 40 mg daily)
• eGFR 30–59: 5–10 mg initial, max 40 mg daily
• eGFR <30: 2.5–5 mg daily, max 40 mg daily

Renal function should be reassessed 1–2 weeks after lisinopril initiation or dose change, and then annually unless comorbidities or signs of decline prompt more frequent monitoring.

Preventive Counseling

Educate patients to:

• Maintain adequate hydration (typically 2–3 liters of fluid daily unless contraindicated by heart failure or hyponatremia)
• Avoid NSAIDs (including over-the-counter ibuprofen and naproxen) as first-line pain relief; use acetaminophen instead
• Report episodes of diarrhea, vomiting, or dehydration immediately, as these may warrant temporary metformin discontinuation
• Notify their provider before any radiologic procedure involving contrast media
• Monitor blood pressure at home if possible; report orthostatic dizziness or syncope

Interaction Monitoring Parameters

After initial stabilization, establish a monitoring cadence:

• Laboratory: Serum creatinine and eGFR every 6–12 months in stable patients, or every 1–3 months in those with declining renal function or recent acute illness
• Clinical: Blood pressure at each visit; symptom screening for orthostasis, volume depletion, or lactic acidosis
• Medication adherence: Verify that the patient is taking doses as prescribed and has not self-adjusted or skipped doses due to side effects

When to Call Your Doctor or Pharmacist

Patients and caregivers should seek immediate medical attention or contact their pharmacy if they experience:

• Signs of lactic acidosis: Nausea, vomiting, abdominal pain, rapid or difficult breathing, muscle pain, unusual fatigue, or dizziness
• Severe hypotension symptoms: Fainting, severe dizziness, chest pain, or shortness of breath unrelated to exertion
• Signs of acute kidney injury: Marked decrease in urine output, sudden weight gain, swelling in legs or face, or back/flank pain
• Acute gastrointestinal illness: Persistent diarrhea or vomiting lasting more than a few hours; metformin may need temporary discontinuation
• Planned contrast exposure: Any radiologic procedure with iodinated contrast requires notification; metformin is typically held 48 hours before and after contrast administration
• Recurrent hypoglycemia: Unexpected or severe low blood sugar episodes, which may indicate drug accumulation or altered glucose metabolism

Key Takeaways

• No direct contraindication exists: Metformin and lisinopril are safe to use together, but the combination requires vigilant monitoring of renal function because both drugs depend on preserved glomerular filtration and active renal tubular secretion.
• Renal function is the critical variable: eGFR-based dose adjustment of metformin is mandatory; lisinopril dosing should also be tailored to GFR. Use the CKD-EPI equation for accuracy, particularly in older adults and those with baseline renal impairment.
• Acute changes warrant intervention: Episodes of dehydration, acute illness, NSAIDs, or contrast exposure require reassessment of both medications and potentially temporary metformin discontinuation until renal function stabilizes.
• High-risk populations need closer follow-up: Patients ≥65 years old, those with CKD stage 3 or higher, and those with diabetic nephropathy should have renal function checked every 3–6 months rather than annually.
• Patient education is essential: Inform patients about hydration, NSAID avoidance, and red flag symptoms of lactic acidosis or severe hypotension. Ensure they understand the importance of medication adherence and reporting acute illness to their provider.

Sources

• FDA Drug Labeling—Metformin Hydrochloride. OpenFDA. https://open.fda.gov
• FDA Drug Labeling—Lisinopril. OpenFDA. https://open.fda.gov
• National Kidney Foundation. KDIGO 2022 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. https://kidney.org
• Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Management in Chronic Kidney Disease. https://kdigo.org
• Inzucchi, S.E., et al. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach. Diabetes Care. 2012;35(6):1364–1379. https://pubmed.ncbi.nlm.nih.gov
• U.S. National Library of Medicine. Lisinopril Monograph. MedlinePlus. https://medlineplus.gov
• U.S. National Library of Medicine. Metformin Monograph. MedlinePlus. https://medlineplus.gov

Your medication safety is our priority. If you are taking metformin, lisinopril, or any other combination of medications, use checkdruginteractions.com to verify your complete medication profile for potential interactions. Enter all of your current prescriptions, over-the-counter drugs, and supplements to receive personalized interaction guidance based on FDA labeling and clinical evidence. When in doubt, speak with your pharmacist—they are your best resource for safe, individualized medication management.